

Discovering

Good drugs for *bad bugs*

and bringing them

to the poor



Saturday, April 9, 1pm
Lunch Seminar | Indian food provided
MIT Bldg. E51, Room 057

Dr. Kishor Wasan

Development and Evaluation of Novel Oral
Lipid-Based Amphotericin B Formulations for
the Treatment of Systemic Fungal Infections
and Visceral Leishmaniasis (VL)

Over 12 million people, most living in extreme poverty, suffer from the parasitic disease Leishmaniasis, also known as Kala-azar. Left untreated, almost all infected individuals will die of the infection.

The only available treatments are expensive, highly toxic, and require daily injections for a month or more by skilled medical personnel.

Dr. Wasan's laboratory has developed a promising drug against leishmaniasis and systemic fungal infections (such as those in AIDS patients) that is safe and easy to use. The powerful and innovative academic licensing agreement that UBC forged with the pharmaceutical company iCo ensures that, the drug, once approved, will be accessible to poor patients in developing countries.

sponsored by the MIT, BU, and Harvard chapters of
Universities Allied for Essential Medicines

www.uaem.org | uaem@mit.edu

